Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Droloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.82 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ESRRG | P62508 | 3/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | ESRRB | O95718 | 2/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | PLD2 | O14939 | 1/20 | 0.82 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Droloxifene SCHEMBL5030004 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28151286 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL30534774 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL30728607 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL4842 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL4843 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL9782633 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28095331 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL750110 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28095329 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738256-B1 | METHOD FOR THE PRODUCTION OF E-1-[4'-(2-DIMETHYLAMINOETHOXY)-PHENYL]-1-(3'-HYDROXYPHENYL)-2-PHENYL-1-BUTENE | KLINGE CO CHEM PHARM FAB (DE) | 1998-04-22 | — | — | EP | claimed |
| US-5693863-A | Method for the production of E-1- 4'- (2- Dimethylaminoethoxy) - Phenyl!-1-(3-Hydroxyphenyl) -2-Phenyl-1-Butene | KLINGE PHARMA GMBH (DE) | 1997-12-02 | — | — | US | claimed |
| US-5047431-A | TREATMENT OF HORMONE-DEPENDENT MAMMARY TUMORS; ANTIESTROGENS | KLINGE PHARMA GMBH & CO. (DE) | 1991-09-10 | — | — | US | claimed |
| EP-3300725-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS WITH SHORT HALF-LIVES AND USES THEREOF | Repros Therapeutics Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20160346295-A1 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof | REPROS THERAPEUTICS INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160038506-A1 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof | REPROS THERAPEUTICS INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-9161940-B2 | Selective estrogen receptor modulators with short half-lives and uses thereof | REPROS THERAPEUTICS INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150031680-A1 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof | REPROS THERAPEUTICS INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2014-07-17 | — | — | US | disclosed |
| US-8765126-B2 | Methods of treating complications and disorders associated with G-CSF administration | SACKSTEIN ROBERT (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| EP-0738256-A1 | METHOD FOR THE PRODUCTION OF E-1-[4'-(2-DIMETHYLAMINOETHOXY)-PHENYL]-1-(3'-HYDROXYPHENYL)-2-PHENYL-1-BUTENE | Klinge Pharma GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
| EP-0738256-A1 | METHOD FOR THE PRODUCTION OF E-1-[4'-(2-DIMETHYLAMINOETHOXY)-PHENYL]-1-(3'-HYDROXYPHENYL)-2-PHENYL-1-BUTENE | Klinge Pharma GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018786-A1 | METHOD FOR THE PRODUCTION OF E-1-[4'-(2-DIMETHYLAMINOETHOXY)-PHENYL]-1-(3'-HYDROXYPHENYL)-2-PHENYL-1-BUTENE | KLINGE PHARMA GMBH (DE) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018786-A1 | METHOD FOR THE PRODUCTION OF E-1-[4'-(2-DIMETHYLAMINOETHOXY)-PHENYL]-1-(3'-HYDROXYPHENYL)-2-PHENYL-1-BUTENE | KLINGE PHARMA GMBH (DE) | 1995-07-13 | — | — | WO | disclosed |
| EP-0313799-B1 | PROCESS FOR THE PREPARATION OF TRANS-1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES | Klinge Pharma GmbH (DE) | 1993-02-10 | — | — | EP | disclosed |
| US-5047431-A | TREATMENT OF HORMONE-DEPENDENT MAMMARY TUMORS; ANTIESTROGENS | KLINGE PHARMA GMBH & CO. (DE) | 1991-09-10 | — | — | US | disclosed |
| US-4960937-A | Process for the preparation of trans-1,1,2-triphenyl-but-1-ene derivatives | KLINGE PHARMA GMBH (DE) | 1990-10-02 | — | — | US | disclosed |
| EP-0313799-A2 | Process for the preparation of trans-1,1,2-triphenyl-but-1-ene derivatives | Klinge Pharma GmbH (DE) | 1989-05-03 | — | — | EP | disclosed |
| EP-0054168-A1 | 1,1,2-Triphenyl-but-1-ene derivatives, process for their manufacture and their use as pharmaceutical agents | Klinge Pharma GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | ESR1 1877/4885ESR2 1542/4885MAPT 4178/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESR2 4164/4885MAPT 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.